Chimeric caspase molecules with potent cell killing activity in apoptosis-resistant cells

L Shearwin-Whyatt1, B Baliga, J Doumanis

  • 1Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, South Australia, 5000, Australia.

Insights

Defective apoptosis leads to hyperproliferation and treatment resistance. Novel chimeric caspases demonstrate potent cell-killing activity against apoptosis-resistant cells, offering a new therapeutic strategy.

Area of Science:

  • Molecular biology
  • Cell biology
  • Biochemistry

Background:

  • Cellular defects preventing apoptosis can cause hyperproliferative disorders.
  • Resistance to apoptosis hinders effective disease treatment.
  • Most apoptosis resistance mechanisms function upstream of caspase activation.

Purpose of the Study:

  • To investigate the therapeutic potential of novel chimeric caspase molecules.
  • To assess the efficacy of these molecules in overcoming apoptosis resistance.

Main Methods:

  • Construction of chimeric caspase molecules: prodomain of caspase-2 fused to caspase-3, tagged with green fluorescent protein (GFP).
  • Transfection of cell lines with varying defects causing apoptosis resistance.
  • Assessment of cell-killing activity of the chimeric caspase molecules.

Main Results:

  • The developed chimeric caspase molecules exhibit potent and rapid cell-killing effects.
  • These molecules are effective in cell lines with diverse defects leading to apoptosis resistance.

Conclusions:

  • Chimeric caspase molecules show promise for treating hyperproliferative disorders.
  • This approach offers a potential strategy to overcome apoptosis resistance in diseases.